Kymera Therapeutics Names Johnson & Johnson Immunology Veteran as Chief Medical Officer
Event summary
- Kymera Therapeutics appoints Terence Rooney, MD, as Chief Medical Officer effective July 27, 2026.
- Dr. Rooney previously led immunology portfolio strategy at Johnson & Johnson.
- He succeeds Jared Gollob, MD, who retires after eight years at Kymera but remains as advisor through year-end.
- Kymera focuses on oral small molecule degrader medicines for immunological diseases.
The big picture
Kymera's appointment of an industry veteran with deep immunology experience underscores its push to advance oral small molecule degraders, a novel therapeutic approach gaining traction in treating immuno-inflammatory diseases. The move comes as biopharmaceutical companies increasingly seek differentiated pipelines to address unmet needs in chronic conditions.
What we're watching
- Pipeline Momentum
- How Dr. Rooney's experience will accelerate Kymera's multiple clinical programs.
- Strategic Expansion
- Whether Kymera can leverage its oral immunology portfolio across new disease areas.
- Leadership Transition
- The pace at which Dr. Rooney integrates and implements his development strategy.